title: Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis.
abstract: BACKGROUND
  Interleukin-2 receptor antagonists (IL-2RAs) have been extensively used in kidney transplant patients to prevent the occurrence of acute rejection. The efficacy and safety of basiliximab and daclizumab, the 2 most commonly used IL-2RAs in clinics, have been compared in a number of randomized controlled trials, but no definite conclusions have been drawn.
  
  
  OBJECTIVE
  This meta-analysis aimed to compare the efficacy and safety of basiliximab and daclizumab in kidney transplant patients.
  
  
  METHODS
  We performed keyword searches in Pubmed, Embase, and the Cochrane library. In total, 6 randomized controlled trials with 509 patients were included in this meta-analysis. Data collected included patient survival, graft survival, acute rejection, infection, and cytomegalovirus infection. The outcome measure was the relative risk of basiliximab versus daclizumab.
  
  
  RESULTS
  Therapy with basiliximab and daclizumab resulted in similar outcomes regarding acute rejection (6-month 95% confidence interval [CI], 0.09-1.14; 12-month 95% CI, 0.53-1.91), patient survival (95% CI, 0.97-1.04), graft survival (95% CI, 0.98-1.08), infection (95% CI, 0.66-1.01), and cytomegalovirus infection (95% CI, 0.45-1.14) within the follow-up period. There were no significant differences in safety and efficacy between the 2 drugs.
  
  
  CONCLUSIONS
  The safety and efficacy of daclizumab and basiliximab are similar in kidney transplant recipients.
authors.affiliation: Department of Urology, Beijing Chaoyang Hospital Affiliated with Capital Medical University, Beijing, China.
authors.forename: Z-J
authors.initials: ZJ
authors.lastname: Sun
authors.affiliation: Department of Urology, Beijing Chaoyang Hospital Affiliated with Capital Medical University, Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Du
authors.affiliation: Department of Urology, Beijing Chaoyang Hospital Affiliated with Capital Medical University, Beijing, China.
authors.forename: L-L
authors.initials: LL
authors.lastname: Su
authors.affiliation: Department of Urology, Beijing Chaoyang Hospital Affiliated with Capital Medical University, Beijing, China.
authors.forename: X-D
authors.initials: XD
authors.lastname: Zhang
authors.affiliation: Department of Urology, Beijing Chaoyang Hospital Affiliated with Capital Medical University, Beijing, China. Electronic address: sunzejia1002@sina.com.
authors.forename: W
authors.initials: W
authors.lastname: Wang
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000077552:Basiliximab; D000077561:Daclizumab; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab